Perjeta Infusion 420 mg/14 mL 1 Vial

Description

Perjeta Infusion (420 mg/14 mL, 1 Vial)

Description: Perjeta (pertuzumab) is a prescription medication used for the treatment of certain types of cancer, particularly HER2-positive breast cancer. It is a monoclonal antibody that works by blocking the HER2 receptor, which is involved in cancer cell growth and survival. This infusion is typically administered intravenously in a healthcare setting, usually in combination with other cancer treatments like trastuzumab and chemotherapy.

Formulation:

Strength: 420 mg per 14 mL vial

Route of Administration: Intravenous (IV) infusion

Appearance: Clear to slightly opalescent solution, colorless to pale yellow

Indications:

HER2-positive breast cancer

Adjuvant and neoadjuvant treatment in combination with trastuzumab and chemotherapy

Metastatic breast cancer treatment

Mechanism of Action: Perjeta binds to the HER2 receptor, preventing the dimerization of HER2 with other receptors like HER3. This interferes with signaling pathways that promote cancer cell growth and survival.

Key Points:

Strength: 420 mg/14 mL

Administration: IV infusion

Indication: HER2-positive breast cancer

Mechanism: Inhibits HER2 receptor dimerization

Side Effects: Includes diarrhea, fatigue, nausea, hair loss, and infusion reactions

Storage:

Store in the refrigerator at 2°C to 8°C (36°F to 46°F)

Protect from light and do not freeze

Note: Perjeta should only be administered under the supervision of a healthcare professional. Always consult your doctor for a personalized treatment plan.